Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of insulin lispro low mixture with insulin glargine when initiating and intensifying insulin therapy as required in patients with type 2 diabetes who have inadequate glycemic control on oral antihyperglycemic medication.

Trial Profile

Comparison of insulin lispro low mixture with insulin glargine when initiating and intensifying insulin therapy as required in patients with type 2 diabetes who have inadequate glycemic control on oral antihyperglycemic medication.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin neutral protamine lispro/insulin lispro (Primary) ; Insulin glargine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PARADIGM
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 13 Jun 2017 Results of post hoc analysis evaluating glycemic profiles of lispro Mix25-treated patients, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 05 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met according to results published in Diabetic Medicine.
    • 05 Jun 2012 Results published in Diabetic Medicine.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top